瑞银-再鼎医药(9688.HK):Vyvgart拉动收入小幅超预期,聚焦下半年关键催化剂-Slight Revenue Beat Driven by Vyvgart;Focus Shifts to Key Catalysts in H2-20260806【15页】

发表回复

后才能评论